List view / Grid view
8 January 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
8 January 2014 | By Quanta Fluid Solutions Ltd
Quanta Fluid Solutions Ltd announces the appointment of John E. Milad as Chief Executive Officer...
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
7 January 2014 | By Boehringer Ingelheim
Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program...
2 January 2014 | By Sanofi
“Sanofi has a history of contributing in this collective effort of sharing clinical trial data and results with researchers and patients with initiatives such as Project Data Sphere..."
2 January 2014 | By GlaxoSmithKline
GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results...
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo Company has received supplemental new drug application (sNDA) approval for Topotecin® injection 40 mg and 100 mg (irinotecan hydrochloride hydrate) for unresectable pancreatic cancer.
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo has received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate)...
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
20 December 2013 | By Merck
This business is based on providing weight management interventions that combine a structured diet, behavior coaching...
20 December 2013 | By Daiichi Sankyo
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan...
